Record growth beats guidance, but QoQ PAT decline flags cost pressure
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Beat FY27 revenue guide (30.5% vs 15-20%), margin guide met (22.8% vs 20-21% sustainable). Sequential PAT decline signals first cost-management miss.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Strong revenue momentum (30.5% YoY) validates diversification strategy, but Q2 PAT fell 10% QoQ despite revenue growth—freight ₹20Cr, acquisition depreciation ₹6-7Cr, labour ₹8Cr pressured margins. European M&A and U.S. order book 3-year targets credible, but execution risk and near-term cost headwinds warrant caution.
₹940.2 Cr
Revenue · +30.5% YoY₹143.5 Cr
Reported PAT · +44.8% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Record Q2 revenue INR940 Cr, YoY growth 30.5%
METDelivered ₹940.2 Cr, +30.5% YoY. Matches reported.
EBITDA ₹214 Cr, margin 22.8%, up 274 bps YoY
METEBITDA margin 22.8% confirmed; growth rate consistent with strong Q2 performance.
PAT ₹144 Cr, up 44.8% YoY
METDelivered ₹143.5 Cr, +44.8% YoY. Matches.
North America ₹421 Cr (45% revenue), Europe ₹405 Cr (43%)
METGeographic split confirmed; Europe +65% YoY vastly exceeds prior ₹180 Cr FY target.
Europe positioned as key long-term driver; 3-year ₹1,000 Cr+ objective
METCurrently ₹405 Cr H1 run rate. On track; M&A (QlinIQ, ABCnow, GmbH) provides infrastructure.
Earnings quality
What changed since the last call
European expansion materially accelerated
UpgradePrior ₹180Cr FY target now exceeded (₹405Cr H1). Three M&A deals (QlinIQ, ABCnow, GmbH) now active. 3-year visibility on Europe.
U.S. order book target quantified
New$225M→$300M over 3 years (explicit). Prior vague bullishness now concrete milestone.
India capacity roadmap formalized
New16B units/year oral solid target; plant acquisition dialogue active, 12-18m timeline.
EBITDA margin guidance reaffirmed at 21%-22%
NeutralRunning 22.8% in Q2, 24% in H1; expect normalization to 21%-22% as freight stabilizes, depreciation absorbs.
The Q&A
Analysts pressed U.S. seasonality, margin ceiling (deflected), capex timing, API costs. Management direct on most; avoided margin upside speculation. Q&A thorough but contained several partial dodges on specific M&A timelines, dividend policy.
U.S. growth and market outlook — Ahmed Madha, Unifi Capital
AnsweredSeasonality key (Q3/Q4 stronger). Order book healthy. Price erosion single digits. Within 3 years target $300M order book from ~$225M.
Europe growth trajectory — Arun, Unifi Capital
PartialNew product launches, pipeline approvals underway. Growth over couple of years to hit ₹6,000Cr objective. No specific ₹X guidance.
Capex and capacity expansion — Saksham Tyagi, Desvelado Advisory
PartialTwo-phase: internal debottleneck + acquire facility (12-18m impact lag). Dialogue with 2 companies, nothing concrete yet.
Manufacturing assets and dosage forms — Mihir Damania, Fident AMC
AnsweredExpanding dosage forms (not injectables). Oral remains core. 2-year horizon for new form scaling. No API backward integration.
Depreciation accounting change — Mihir Damania, Fident AMC
AnsweredChanged intangible asset treatment Q2 (indefinite→finite 10-year life). QlinIQ, ABCnow amortization starting. Expect similar run rate next 2 quarters.
U.S. OTC channel strategy — Akshit Shetty, Manjit Kothari Family Office
AnsweredAlready positioned with retailers; dialogues on innovation/launches. Some retailers seeking innovation direction from us.
European M&A and product introduction — Akshit Shetty, Manjit Kothari Family Office
PartialQlinIQ (Netherlands), ABCnow (Germany) deals live. Each market differs. Both add tangible and intangible growth. More M&A likely in next 12m.
Australia growth and Nova subsidiary — Pranav Gupta, Value Advisors
Answered100% of Australia via Nova. Scaling to $100M subsidiary over 3 years. Nova is front-end, not manufacturing.
Revenue run-rate targets and capex cycle — Tanvi, Mira Capital
AnsweredTrending near INR1,000Cr/quarter; next year should touch INR4,000Cr run rate. Capex coming for manufacturing to hit INR5,000Cr+ target.
API cost pressures and gross margin outlook — Arun, Unifi Capital (repeat)
AnsweredExpect 21%-22% EBITDA going forward. If crude eases, margin upside. If crude up, headwind. Retailers won't accept price increases.
Margin ceiling and upside scenario — Harshali, ASK Wealth Advisors
DodgedAlways a possibility, but for that you've got to call the president and call off the war. 21%-22% range expected.
R&D focus and competitive positioning — Vishal Manchanda, Systematix Institutional Equities
AnsweredNiche oral solids where competition is lower. No injectables. Competitors facing same cost pressures. Growth from volume, geography, mix—not pricing power.
Organic vs inorganic growth split — Vishal Manchanda, Systematix Institutional Equities
AnsweredU.K. 20% new launches. Europe 50%-60% new launches. U.S. 10%. Geographic diversification is bigger driver.
Lease liability increase and U.K. expansion — Arun, Unifi Capital (repeat)
AnsweredNew lease in U.K. from geographic expansion. Consolidation ongoing.
Guidance
FY27 revenue growth 15-20% reaffirmed
HighTracking +30.5% YoY; guidance conservative. H2 seasonality favorable, but geopolitical headwinds may moderate.
INR4,000Cr annual run rate achievable next year
HighCurrently INR1,000Cr/quarter; organic growth + Europe contribution support.
U.S. order book $225M→$300M over 3 years
HighExplicit target; price erosion single digits; multiple ANDAs in pipeline.
EBITDA margin 21%-22% range going forward
HighCurrently 22.8% Q2, 24% H1; expect mean reversion as freight, depreciation stabilize.
Gross margin normalize to 55%-56% (prior guidance)
MediumCurrently 58.5%, above target. Q1 inventory benefit, Q2 freight headwind. Volatility expected Q3/Q4.
Indian manufacturing acquisition/expansion in 12-18 months
MediumDialogue active; major capex required for ₹5,000-6,000Cr revenue targets.
Risks the call surfaced
Geopolitical supply chain disruption
MediumRed Sea shipping delays affecting Middle East and ROW markets. Q2 shipment timing impacted; expected recovery by FY27 end.
Input cost inflation
MediumParacetamol, ibuprofen APIs at elevated levels. Freight up ₹20Cr Q2. Retailers resisting price increases.
U.S. price erosion
MediumSingle-digit price erosion ongoing in U.S. OTC market. Geopolitical uncertainty moderating consumer sentiment.
M&A integration execution
MediumQlinIQ, ABCnow ramping; future Indian plant acquisition pending. Integration delays could impact revenue/margin targets.
Management
Score 7/10. Direct on financials, conservative on timelines (Europe 3-year, M&A 12-18m). Deflected margin upside question. Mostly transparent on cost headwinds. Beat FY27 revenue guidance (30.5% vs 15-20%). EBITDA margin met (22.8% vs 20-21%). Sequential PAT decline not frontally addressed; signal of margin pressure.
1 · Q3 FY27
Seasonally stronger quarter; winter cold-season demand peak
2 · Next 12m
5-6 ANDA approvals expected; European M&A integration (QlinIQ, ABCnow ramp)
3 · Next 12-18m
Indian manufacturing asset acquisition; 16B units/year capacity target
order book 3-year targets credible, but execution risk and near-term cost headwinds warrant caution.
Record growth, margin resilience tested
Revenue beat guidance at +30.5% YoY, but profit declined 10% QoQ despite 11.8% revenue growth—₹35 crore in freight, depreciation, and labour headwinds offset gross margin gains. The Q3 profit recovery will define whether this is a temporary cost squeeze or a structural margin problem.
₹940.2 Cr
+30.5% YoY, +11.8% QoQ
22.8%
+274 bps YoY; H1 24%, tracking 21–22% guidance
₹143.5 Cr
+44.8% YoY, but -10% QoQ from ₹159 Cr Q1
58.5%
+135 bps YoY; above 55–56% normalized target
On revenue and margins, Marksans delivered a record quarter. On profit, it stumbled. Quarter-on-quarter, net income fell to ₹143.5 crore from ₹159 crore despite revenue climbing 11.8%—the first sign that cost pressures may be more durable than the call suggests. Understanding where that ₹15.5-crore profit gap came from, and whether it heals in Q3, is the real earnings story.
Where the profit decline came from
The company quantified three Q2 headwinds: freight ₹20 crore (Red Sea disruptions), intangible asset depreciation ₹6–7 crore (QlinIQ and ABCnow acquisitions now amortizing on a finite 10-year schedule), and labour costs ₹8 crore higher year-on-year. That totals ₹34–35 crore in incremental expenses. Yet profit fell only ₹15.5 crore QoQ. The offset came from gross margin expansion—inventory benefits that lifted Q1 wore off, Q2 saw lower sourcing costs, and that gross margin gain (roughly ₹19–20 crore, embedded in the 58.5% print) nearly broke even on the headwinds. The fragility is now apparent: if freight normalizes but labour and depreciation stick, and if gross margin reverts to the 55–56% target as management expects, profit has no cushion for the next stumble.
₹20 Cr
Sequential headwind; expected to normalize
₹6–7 Cr
New finite-life accounting; recurring for 2+ quarters minimum
₹8 Cr
YoY headwind; ongoing structural cost
~₹20 Cr
Temporary benefit; expected to normalize to 55–56%
Management's claims vs. what holds up
Record Q2 revenue ₹940 Cr, YoY +30.5%, beating FY27 guidance of 15–20%
Delivered ₹940.2 Cr, +30.5% YoY. H1 ₹1,781 Cr (+32.9% YoY). Guidance was conservative.
Supported
EBITDA margin 22.8%, above 20–21% sustainable target; expect 21–22% by FY27 end
Q2 22.8%, H1 24%. Running above midpoint; normalization to 21–22% as freight stabilizes and depreciation absorbs.
Supported; normalization risk embedded
Europe ₹405 Cr H1 (+65% YoY) now tracking ₹1,000+ Cr 3-year target; $300M U.S. order book in 3 years
Europe ₹405 Cr confirmed (QlinIQ ₹84 Cr, ABCnow ramping). U.S. price erosion single digits, order book credible. Targets explicit, roadmap clear.
Supported; execution risk on M&A synergies
PAT +44.8% YoY shows operational leverage intact
PAT ₹143.5 Cr YoY +44.8%, but -10% QoQ. YoY leans on weak Q2 FY26 base; QoQ decline flags near-term profit headwind.
Overstated (trend deteriorating despite YoY beat)
What changed on this call
Europe acceleration formalized: ₹180 Cr FY target exceeded; three M&As (QlinIQ, ABCnow, GmbH) now active
U.S. order book target quantified: $225M → $300M over 3 years, with explicit ANDA pipeline
Depreciation accounting changed: intangibles to finite 10-year life; ₹6–7 Cr every quarter for 8+ quarters ahead
Indian manufacturing acquisition in active dialogue: 12–18 month timeline, 16B units/year target
Freight and labour cost headwinds quantified for first time; geopolitical risk explicitly tied to Red Sea
The bull case
Revenue growth is accelerating, not decelerating. At +30.5% YoY, Marksans is far outpacing its prior guidance and building geographic diversification: North America 45%, Europe 43%, each its own market. The European acquisition roadmap (QlinIQ, ABCnow, GmbH) is converting early momentum into structural presence—₹405 Cr H1 on a ₹180 Cr full-year prior target is not a blip. The U.S. order book, now explicitly quantified at $300M in 3 years, is backed by 5–6 pending ANDAs and tangible retailer partnerships. Capex is coming (Indian plant, dosage-form expansion), but balance-sheet strength (₹1,095 Cr net cash) supports both M&A and growth investment without stress. Management's long-term targets (₹5,000–6,000 Cr revenue, Europe ₹1,000+ Cr) are concrete and have operational moats behind them.
The bear case
Profit quality is deteriorating even as revenue accelerates. A ₹15.5-crore QoQ profit decline on 11.8% revenue growth is a profitability miss that no margin-expansion story fully explains. The three cited headwinds (freight ₹20 Cr, depreciation ₹6–7 Cr, labour ₹8 Cr) total ₹34–35 crore and will recur in Q3 unless freight normalizes (geopolitical outcome uncertain) or M&A synergies offset them (execution risk). Depreciation is now ₹6–7 Cr every quarter for at least 8+ quarters—a permanent earnings drag from M&A. Gross margin at 58.5% exceeds the 55–56% normalized target; when it normalizes, that ₹19–20 Cr offset disappears and profit becomes even more vulnerable. The market is pricing in the growth story at ₹322, sitting 31% above the 200-day average and only -10% from all-time high, leaving almost no room for execution stumbles. If Q3 profit doesn't recover alongside seasonal strength, the Hold becomes a Sell.
How the street is positioned
The stock closed at ₹322.15, trading 31% above its 200-day moving average (₹246.02), comfortably above the 50-day (₹318.36) and 20-day (₹305.67). It sits -10.19% from its all-time high of ₹358.7 but +107.84% from its 52-week low of ₹155. The RSI of 56.3 is neutral—neither overbought nor oversold. Volume is normal, not panic or euphoria. FII ownership is steady at 17.47% (up just 0.71 pp QoQ), and DII at 6.19% (down 0.38 pp). No concerning bulk or block deals—only routine Microcurves trading. Institutional positioning is cautiously bullish, not overcommitted. The price action confirms the fundamental story (revenue and geography are strong) but prices in near-term margin challenges (the stock remains -10% from highs despite a beat). A Q3 profit recovery would likely see the stock test the all-time high; a continued decline would trigger a 5–10% retracement. The market is balanced, not fragile.
1. QoQ profit decline recurs in Q3 despite seasonal strength
HighA -10% QoQ PAT decline on +11.8% revenue growth is a profitability miss. If it repeats in Q3 (typically stronger), the margin resilience story breaks, guidance (21–22% EBITDA) will be in doubt, and the stock re-rates lower.
2. Gross margin normalizes from 58.5% to 55–56%
MediumGross margin is 135 bps above normalized target. Q1 inventory benefits fading, Q2 sourcing gains temporary. When it normalizes, the ₹19–20 Cr buffer that offset Q2 headwinds disappears.
3. Depreciation ₹6–7 Cr is permanent, not transient
MediumChanged intangible-asset accounting; QlinIQ and ABCnow now amortize over 10 years. This is baked into earnings for 8+ quarters. Every unplanned rupee of depreciation is a direct PAT miss.
4. Red Sea freight tailwind doesn't materialize; disruptions persist
Medium₹20 Cr Q2 freight was attributed to geopolitical disruption. If disruptions persist into Q3/Q4, freight stays elevated and the full ₹34–35 Cr headwind waterfall moves against the company.
5. European M&A integration misses synergy targets
MediumQlinIQ (₹84 Cr revenue H1) and ABCnow (ramping) are moving the dial, but if integration stalls or capex timelines slip, the 3-year ₹1,000+ Cr Europe target is at risk and stock re-rates on execution doubt.
6. U.S. price erosion accelerates beyond single digits
LowOTC retailer pressure and geopolitical uncertainty are holding price erosion to single digits. If competition intensifies or demand softens, erosion could accelerate and pressure revenue growth.
1 · Q3 PAT recovery
Seasonally, Q3 is the strongest quarter. If PAT grows alongside revenue, the QoQ decline was a transient cost squeeze. If profit falls again despite seasonal strength, the margin resilience story breaks and Hold becomes Sell.
2 · Freight cost normalization signal
Management expects ₹20 Cr Q2 freight to normalize. Watch for Q3 colour on Red Sea recovery or continued disruptions. A stuck ₹20 Cr headwind is a permanent earnings drag.
3 · European M&A synergy signals
QlinIQ contributed ₹84 Cr H1; ABCnow is ramping. Watch for cross-selling signals, Marksans product-introduction timelines into Europe, and German subsidiary path to profitability. This is the long-term growth driver.
Marksans is a geographic diversification story in motion, not a single-region generics player anymore. Revenue growth is genuine, margins are resilient on paper, and the long-term targets (Europe ₹1,000+ Cr, U.S. $300M in 3 years) are credible. But Q2 reveals a company under near-term cost pressure, and profit quality is deteriorating faster than the headline growth suggests.
This is a steady-execution story, not a step-change. The one number to track from here is Q3 profit. Profit growth > 0 (or at minimum profit stability) alongside seasonal strength would justify buying the -10% drawdown from all-time highs. A repeated profit decline would signal execution risk and warrant a reset lower. Until Q3 lands, Hold is the right call.
RedTape Q2 FY27: consolidated PAT +27% YoY to ₹34.9 Cr, revenue down 3.6%
PAT +26.83% YoY · revenue -3.57% · margins expanding
₹474.84 Cr
-3.57% YoY
₹34.93 Cr
+26.83% YoY
7.14%
+1.6pp YoY
₹0.63
RedTape's consolidated PAT rose 26.8% YoY to ₹34.93 Cr in Q2 FY27 (quarter ended September 30, 2026), on consolidated revenue of ₹474.84 Cr, down 3.6% YoY and 1.3% QoQ from Q1 FY27's ₹481.28 Cr. Basic EPS was ₹0.63 versus ₹0.50 a year ago. Standalone tracked closely — PAT ₹35.60 Cr on revenue ₹474.30 Cr — with the roughly 1.9% consolidated shortfall coming from the overseas step-down subsidiaries (Redtape HK, Redtape London, Redtape Quanzhou). Sequentially, PAT fell 21.5% from Q1's record ₹44.48 Cr (publicly flagged then as the company's "highest-ever Q1 profit"), which reads as the normal seasonal step-down for a footwear/apparel retailer — Q1 (Apr-Jun) captures the summer season while Q2 is typically softer ahead of the festive Q3 — rather than a deterioration. No exceptional items were booked in either the current or year-ago quarter, so the YoY PAT growth is purely operational.
Q2 FY-2027 vs prior quarters
The YoY profit growth came entirely from margin expansion, not volume: operating margin (EBITDA/revenue) improved to roughly 15.75% from 14.78% a year ago, and net margin to roughly 7.1% from roughly 5.5% (PAT/total-income basis, consistent with how prior quarters are tracked), even as revenue contracted. The swing driver was working capital: the company built ₹132.8 Cr of inventory this quarter versus a ₹24.9 Cr drawdown a year ago, cutting net material cost (cost of materials plus stock-in-trade purchases minus the inventory change) to ₹259.1 Cr from ₹305.4 Cr YoY. Finance costs also fell 15.2% YoY to ₹15.94 Cr on lower borrowings, partly offset by an 18.3% rise in depreciation to ₹25.74 Cr as new-store capex and right-of-use assets grow. Sequentially, both margins compressed from Q1's stronger 17.36% OPM / 8.96% NPM — consistent with the seasonal Q1-to-Q2 step-down rather than a new trend.
The stock went into the print at ₹103.8, down 8.8% over the past month of trading.
Store expansion targeting 150 outlets in FY27 (33 opened Q1). Revenue to follow historical growth trajectory; EBITDA margin to remain stable around 20%. E-commerce aspires to return to 30% of revenue from current 22%.
— This quarter: missed
RedTape remains thinly covered — a single analyst tracks the stock (Hold, ₹166 target per TipRanks) — and no Q2 FY27-specific consensus estimate could be found, so the print cannot be benchmarked against the Street with confidence; vsStreet is marked unknown rather than guessed. Against management's own August concall guidance — revenue to "follow the historical growth trajectory" and EBITDA margin to hold "stable around 20%," alongside a push toward 150 new outlets in FY27 (33 opened in Q1) and e-commerce returning to 30% of revenue from 22% — the quarter falls short on both headline metrics: revenue declined rather than grew, and operating margin at roughly 15.75% sits well below the 20% band even though it improved YoY. The filing discloses no Q2 store count or e-commerce revenue split, so those two guidance threads can't be verified from this result alone. No management press release accompanied this filing, so there is no company framing of the quarter to cross-check against the numbers. The auditors' limited-review report repeats an emphasis of matter from Q1: an income-tax department search at company and director premises in September 2025, whose financial impact remains "currently not ascertainable" in both the standalone and consolidated statements.
W1
Revenue trajectory: guided to 'follow the historical growth trajectory' but printed -3.6% YoY to ₹474.84 Cr — watch for a return to growth in festive Q3
W2
EBITDA margin: guided 'stable around 20%'; Q2 OPM was ~15.75% (Q1: 17.36%) — watch if H2 closes the gap to the guided band
W3
Store count: 33 of a targeted 150 FY27 outlet additions were open after Q1; this filing discloses no updated Q2 count — watch next disclosure against the 150-store target